• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical and experimental allergy : >Efficacy of fluticasone furoate nasal spray vs. placebo for the treatment of ocular and nasal symptoms of allergic rhinitis: a systematic review.
【24h】

Efficacy of fluticasone furoate nasal spray vs. placebo for the treatment of ocular and nasal symptoms of allergic rhinitis: a systematic review.

机译：糠酸氟替卡松鼻喷雾剂与安慰剂在治疗过敏性鼻炎的眼和鼻症状方面的疗效：系统评价。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Although previous data suggest that intranasal fluticasone furoate (FF) improves ocular symptoms of allergic rhinitis (AR), it presents serious limitations that question its results and conclusions. Therefore, an independent systematic review with meta-analysis is required to confirm and clarify the magnitude of the effect of FF. METHODS: This review compared the efficacy of intranasal FF to placebo on ocular and nasal symptoms in patients with AR. Primary outcomes were reflective and instantaneous total ocular symptom scores (rTOSS and iTOSS), and reflective and instantaneous total nasal symptom scores (rTNSS and iTNSS). Secondary outcomes included the assessment of response to therapy, quality of life (QoL), and adverse effects. RESULTS: Sixteen trials (5.348 patients) were selected. Seven studies included seasonal AR patients and nine studies, perennial AR patients. Intranasal FF significantly improved rTOSS and iTOSS scores compared with placebo in patients with seasonal (weighted mean difference [WMD] -0.54, 95% CI, -0.70 to -0.37, and -0.59, 95% CI, -0.76 to -0.43) and perennial AR (-0.33, 95% CI, -0.31 to -0.05, and -0.38, 95% CI, -0.69 to -0.07). Intranasal FF was also significantly more effective in improving rTNSS and iTNSS scores in seasonal (WMD=-1.14, 95% CI, -1.57 to -0.72, and -1.32, 95% CI, -1.64 to -1.01) and perennial AR patients (-0.83, 95% CI, -1.08 to -0.59, and -0.90, 95% CI, -1.33 to -0.48). Finally, there were greater improvements in response to therapy and QoL with a favourable safety profile. CONCLUSIONS AND CLINICAL RELEVANCE: Intranasal FF showed a consistent ocular and nasal efficacy along with improvement in QoL in AR patients. This review provides significant evidence that treatment with FF nasal spray at a dose of 110 mcg once daily is effective in relieving ocular and nasal symptoms in adolescents and adults with AR.
机译：背景：尽管以前的数据表明鼻内糠酸氟替卡松（FF）改善了过敏性鼻炎（AR）的眼部症状，但它仍然存在严重的局限性，质疑其结果和结论。因此，需要通过荟萃分析进行独立的系统评价，以确认和阐明FF影响的大小。方法：本研究比较了鼻内FF和安慰剂对AR患者眼和鼻症状的疗效。主要结果是反射性和瞬时总眼部症状评分（rTOSS和iTOSS）以及反射性和瞬时总鼻部症状评分（rTNSS和iTNSS）。次要结果包括对治疗反应，生活质量（QoL）和不良反应的评估。结果：选择了十六项试验（5.348例患者）。七项研究包括季节性AR患者，九项研究包括常年性AR患者。与安慰剂相比，季节性患者（加权平均差异[WMD] -0.54、95％CI，-0.70至-0.37和-0.59、95％CI，-0.76至-0.43），鼻内FF显着改善了rTOSS和iTOSS评分。多年生AR（-0.33，95％CI，-0.31至-0.05，和-0.38，95％CI，-0.69至-0.07）。鼻内FF在改善季节性（WMD = -1.14，95％CI，-1.57至-0.72和-1.32，95％CI，-1.64至-1.01）和常年性AR患者的rTNSS和iTNSS评分上也更有效。 -0.83、95％CI，-1.08至-0.59和-0.90、95％CI，-1.33至-0.48）。最后，在安全性良好的情况下，对治疗和生活质量的反应有了更大的改善。结论和临床意义：鼻内FF在AR患者中表现出一致的眼和鼻功效以及QoL的改善。这篇综述提供了重要的证据，每天一次110 mcg FF鼻喷剂治疗可有效缓解AR的青少年和成人的眼和鼻症状。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号